t” benchmark. This follows a drawn-out sale process. Spire launched a strategic review in September 2025 after pressure from Harwood Capital Management, a hedge fund, and later held talks with private equity firms Bridgepoint and Triton before Triton exited. Operationally, Spire says trading through April matched expectations, and it expects 2026 adjusted core profit – a profit measure that strips out one-offs – to be broadly in line with 2025.
Why should I care?
For markets: A June 11 deadline turns the price gap into a live vote.
With the stock around 215.5p, the distance to 250p is effectively the market’s estimate of deal risk. That spread will move with signals on financing, whether other buyers emerge, and how confident investors are that a major shareholder is willing to pay up. The deadline forces clarity: a firm offer could pull the shares closer to the bid, while a walkaway could send them back toward a fundamentals-only valuation.
Zooming out: Old reference prices can linger even when the business changes.
The headline number is familiar: Toscafund built its stake to nearly 11% while opposing Ramsay Health Care’s 250p approach in 2021, and it’s now using the same price. That kind of anchor can matter even though Spire’s shares remain well below their 411p high from 2016 and costs have risen across UK health care. With profit expected to be flat, shareholders are judging whether yesterday’s price still fits today’s growth outlook.
